Medpace's stock soared 5.08% during intraday trading on Friday, reflecting significant investor interest.
The surge follows an upgrade by Jefferies analyst David Windley, who raised the rating on Medpace from Hold to Buy with a price target of $560, citing positive developments in biotech funding.